At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SBEV Splash Beverage Group Inc.
Post-Mkt 07-10 16:03:21 EDT
0.1455
-0.0198
-11.98%
盘后0.1416
-0.0039-2.68%
16:01 EDT
High0.1590Low0.1415Vol5.23M
Open0.1563D1 Closing0.1653Amplitude10.59%
Mkt Cap2.24MTradable Cap2.21MTotal Shares15.39M
T/O781.20KT/O Rate34.49%Tradable Shares15.16M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NYSE American Accepts Splash Beverage Compliance Plan, Sets Jan. 29, 2027 Deadline to Regain Listing Standards
Reuters  ·  07-09 21:05
NYSE American Accepts Splash Beverage Compliance Plan, Sets Jan. 29, 2027 Deadline to Regain Listing Standards
Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation
THOMSON REUTERS  ·  07-09 21:00
Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation
Top Premarket Decliners
MT Newswires Live  ·  07-07
Top Premarket Decliners
Argent Biopharma Ltd - to Receive a 15% Net Revenue Royalty on Future Sbev Global Cannepil Revenues
THOMSON REUTERS  ·  07-07
Argent Biopharma Ltd - to Receive a 15% Net Revenue Royalty on Future Sbev Global Cannepil Revenues
Argent Biopharma - Enters a Global Licensing Transaction for Cannepil with Splash Beverage Group Inc
THOMSON REUTERS  ·  07-07
Argent Biopharma - Enters a Global Licensing Transaction for Cannepil with Splash Beverage Group Inc
Argent Biopharma - Transaction Includes $5.5 Mln Upfront Consideration for Global Licensing Rights
THOMSON REUTERS  ·  07-07
Argent Biopharma - Transaction Includes $5.5 Mln Upfront Consideration for Global Licensing Rights
Splash Beverage Group Secures Exclusive Worldwide License to Argent Biopharma’s Cannepil Epilepsy Drug
Reuters  ·  07-07
Splash Beverage Group Secures Exclusive Worldwide License to Argent Biopharma’s Cannepil Epilepsy Drug
Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil
MT Newswires Live  ·  07-06
Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil
Mercer Street Fund Forgives USD 5 Million Argent Biopharma Debt in Cannepil Licensing Deal with Splash Beverage Group
Reuters  ·  07-06
Mercer Street Fund Forgives USD 5 Million Argent Biopharma Debt in Cannepil Licensing Deal with Splash Beverage Group
Splash Beverage Group - Argent Biopharma to Receive 15% Royalty on Worldwide Cannepil Sales
THOMSON REUTERS  ·  07-06
Splash Beverage Group - Argent Biopharma to Receive 15% Royalty on Worldwide Cannepil Sales
Splash Beverage Group Acquires Exclusive Global Rights to Cannepil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
THOMSON REUTERS  ·  07-06
Splash Beverage Group Acquires Exclusive Global Rights to Cannepil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
Splash Beverage Group - Buys Exclusive Worldwide Rights to Develop and Sell Cannepil
THOMSON REUTERS  ·  07-06
Splash Beverage Group - Buys Exclusive Worldwide Rights to Develop and Sell Cannepil
Splash Beverage Group - Issues $5.5 Mln Preferred Equity; $5 Mln Argent Biopharma Debt Forgiven as License Consideration
THOMSON REUTERS  ·  07-06
Splash Beverage Group - Issues $5.5 Mln Preferred Equity; $5 Mln Argent Biopharma Debt Forgiven as License Consideration
Splash Beverage Group - Secures $1 Mln Strategic Investment from C/M Capital Partners for Cannepil Development
THOMSON REUTERS  ·  07-06
Splash Beverage Group - Secures $1 Mln Strategic Investment from C/M Capital Partners for Cannepil Development
Splash Beverage Sells 767,953 Shares in Private Placement for Gross Proceeds of $117,036
Reuters  ·  06-27
Splash Beverage Sells 767,953 Shares in Private Placement for Gross Proceeds of $117,036
Splash Beverage Group COO Michael Bondurant files initial beneficial ownership statement
Reuters  ·  06-19
Splash Beverage Group COO Michael Bondurant files initial beneficial ownership statement
Press Release: Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
Dow Jones  ·  06-15
Press Release: Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
Splash Beverage invests $217,479.24 in Avicanna private placement, buys 2 million shares and 1 million warrants
Reuters  ·  06-13
Splash Beverage invests $217,479.24 in Avicanna private placement, buys 2 million shares and 1 million warrants
Splash Beverage files to sell 10M shares of common stock for holders
TIPRANKS  ·  06-13
Splash Beverage files to sell 10M shares of common stock for holders
Splash Beverage Group - C/M Capital Master Fund May Resell up to 10 Mln Splash Beverage Group Shares - SEC Filing
THOMSON REUTERS  ·  06-13
Splash Beverage Group - C/M Capital Master Fund May Resell up to 10 Mln Splash Beverage Group Shares - SEC Filing

Introduction

Company Name.
Splash Beverage Group Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Splash Beverage Group, Inc. engages in the manufacturing, distribution, marketing, and sale of various beverages in the United States. The company's products include flavored tequilas under the SALT Naturally Flavored Tequila name; hydration and energy products under the TapouT Performance name; wine under the Copa di Vino name; and Pulpoloco Sangria. It also sells beverages and groceries online through qplash.com. The company is based in Fort Lauderdale, Florida.
Issue price:
--